Placenta Extract Gel as a Periodontal Local Delivery Drug
Launched by SUEZ CANAL UNIVERSITY · Jul 11, 2024
Trial Information
Current as of September 23, 2025
Completed
Keywords
ClinConnect Summary
Group I: (control group): where subgingival scaling and root planning will be performed and the pocket will be allowed to heal with secondary intention. Group II (test group): where subgingival scaling and root planing, and 1ml of human placental extracts gel\* adsorbed in 30 beads of gelatin foam of 1sq. mm, will be placed into the pockets with the help of a probe to fill the sulcus to the deepest point \& coepak will be placed. patients will be recalled after seven 12 days to remove the coePak. A customized acrylic stent will be fabricated for each patient to provide a reproducible insert...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - having a pocket of 4-5 mm ( grade B stage II periodontitis).
- Exclusion Criteria:
- • patients with known systemic conditions like Diabetes mellitus, hypertension, atherosclerosis, and other conditions known to affect periodontal status adversely.
- • patients suffering from stage III grade C periodontitis.
- • pregnant and lactating women,
- • known harmful habits like alcohol consumption, and tobacco.
- • any form of periodontal therapy during the last six months \& antimicrobial therapy during the last 3 months.
About Suez Canal University
Suez Canal University is a distinguished academic institution dedicated to advancing medical research and education in the region. As a clinical trial sponsor, the university focuses on conducting innovative studies that aim to enhance patient care and outcomes. Leveraging its strong network of healthcare professionals and state-of-the-art facilities, Suez Canal University fosters collaboration between researchers and clinicians to explore new therapeutic approaches and validate clinical practices. Committed to ethical standards and scientific rigor, the university plays a pivotal role in contributing to the global body of medical knowledge and improving healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ismailia, Egypt
Patients applied
Trial Officials
dalia fayad, Phd
Principal Investigator
Suez Canal University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported